EntryPoint Capital’s Monte Rosa Therapeutics GLUE Stock Holding History

EntryPoint Capital’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-33,219	Closed	-$176K	–	817
2024 Q3	$176K	Buy	+33,219	New	+$168K	0.1%	497
2024 Q2	–	Sell	-15,893	Closed	-$112K	–	1177
2024 Q1	$112K	Buy	+15,893	New	+$94.3K	0.1%	350

Other funds holding GLUE

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EntryPoint Capital's GLUE Position: Q4 2024 in Review

EntryPoint Capital sold out of Monte Rosa Therapeutics (GLUE) in Q4 2024, closing a stake of 33,219 shares — an estimated $176K sold.

EntryPoint Capital first reported a position in GLUE in Q1 2024 and held it in 2 quarters. The position peaked at $176K in Q3 2024. 104 funds tracked by Wall St. Rank hold GLUE as of Q4 2024.

EntryPoint Capital reported no remaining Monte Rosa Therapeutics position as of Q4 2024 after selling out during the quarter.
EntryPoint Capital sold 33,219 Monte Rosa Therapeutics shares in Q4 2024, an estimated $176K.
EntryPoint Capital first reported a position in Monte Rosa Therapeutics in Q1 2024 and held it in 2 quarters.
EntryPoint Capital's Monte Rosa Therapeutics position peaked at $176K in Q3 2024.
104 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q4 2024.

Based on EntryPoint Capital's 13F filing for Q4 2024, filed 11 Feb 2025.